Using EMT signature analysis in patients with non-small cell lung carcinoma in clinical trials and in animal model studies, EMT-like mesenchymal cells showed significantly greater resistance to EGFR and PI3K/AKT pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies [97]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.